Granisetron-mediated augmentation of sertraline therapeutic effect in obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial

Granisetron-mediated augmentation of sertraline therapeutic effect in obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial

Abstract Background Medications currently recommended for the treatment of Obsessive-Compulsive Disorder (OCD) usually relieve the severity of symptoms by as much as 20–30%, and satisfactory treatment is obtained in 40–60% of patients with OCD. Nevertheless, the remaining symptoms continue to impair...

Full description

Bibliographic Details
Main Authors: Ala Ghobadian, Saba Mokhtari, Behnam Shariati, Leila Kamalzadeh, Mohsen Shati, Mehrdad Eftekhar Ardebili, Masoomeh Yarahmadi, Mohammadreza Shalbafan
Format: Article
Language:English
Published: BMC 2022-09-01
Series:BMC Pharmacology and Toxicology
Subjects:
Serotonin 5-HT3 receptor
Obsessive-compulsive disorder
Randomized controlled trial
Selective serotonin reuptake inhibitors
Granisetron
Online Access:https://doi.org/10.1186/s40360-022-00610-5

Internet

https://doi.org/10.1186/s40360-022-00610-5

Similar Items